The outlook for drug development to treat rare diseases looks encouraging, offering hope to the 300 million people globally facing the significant challenges of these often-overlooked condi
Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products
Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
Applied Therapeutics plummets after the FDA turns down its marketing application for govorestat as a treatment for galactosaemia
Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Editor's Picks
